As we identified SF3B1-mutated AML as highly responsive to S767 (Fig. 1, H and I) and optimized UM4118 activity on ABCB7 depleted cells (Fig. 4A), we tested UM4118 potency in a panel of 14 primary AMLs carrying or not SF3B1 mutations. The gene discussed is SF3B1; the disease is acute myeloid leukemia.